184 related articles for article (PubMed ID: 26109475)
1. Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab.
Meister MT; Voss S; Schwabe D
Pediatr Blood Cancer; 2015 Nov; 62(11):2018-20. PubMed ID: 26109475
[TBL] [Abstract][Full Text] [Related]
2. Comment on: Treatment of EBV-Associated Nodular Sclerosing Hodgkin Lymphoma in a Patient With Ataxia Telangiectasia With Brentuximab Vedotin and Reduced COPP Plus Rituximab.
Zielen S
Pediatr Blood Cancer; 2016 May; 63(5):946. PubMed ID: 26719151
[No Abstract] [Full Text] [Related]
3. Reply to Comment on: Treatment of EBV-Associated Nodular Sclerosing Hodgkin Lymphoma in a Patient With Ataxia Telangiectasia With Brentuximab Vedotin and Reduced COPP Plus Rituximab.
Meister MT; Voss S; Schwabe D
Pediatr Blood Cancer; 2016 May; 63(5):947. PubMed ID: 26739927
[No Abstract] [Full Text] [Related]
4. [Treatment of advanced Hodgkin lymphoma].
Kreissl S; Borchmann P
Dtsch Med Wochenschr; 2013 Jun; 138(23):1212-4. PubMed ID: 23720173
[No Abstract] [Full Text] [Related]
5. Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma.
Fizesan M; Boin C; Aujoulat O; Newinger G; Ghergus D; Watier H; Lustig H; Ojeda-Uribe M
J Oncol Pharm Pract; 2016 Feb; 22(1):188-92. PubMed ID: 25586990
[No Abstract] [Full Text] [Related]
6. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
[TBL] [Abstract][Full Text] [Related]
7. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
8. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma.
Cao H; Yamamoto K; Yang LX; Weber R
Anticancer Res; 2013 Sep; 33(9):3879-85. PubMed ID: 24023323
[TBL] [Abstract][Full Text] [Related]
10. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials.
Behringer K; Mueller H; Goergen H; Thielen I; Eibl AD; Stumpf V; Wessels C; Wiehlpütz M; Rosenbrock J; Halbsguth T; Reiners KS; Schober T; Renno JH; von Wolff M; van der Ven K; Kuehr M; Fuchs M; Diehl V; Engert A; Borchmann P
J Clin Oncol; 2013 Jan; 31(2):231-9. PubMed ID: 23150709
[TBL] [Abstract][Full Text] [Related]
11. Fertility in males treated for Hodgkins disease with COPP/ABV hybrid.
Hobbie WL; Ginsberg JP; Ogle SK; Carlson CA; Meadows AT
Pediatr Blood Cancer; 2005 Feb; 44(2):193-6. PubMed ID: 15390272
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
Shemesh CS; Agarwal P; Lu T; Lee C; Dere RC; Li X; Li C; Jin JY; Girish S; Miles D; Lu D
Cancer Chemother Pharmacol; 2020 May; 85(5):831-842. PubMed ID: 32222808
[TBL] [Abstract][Full Text] [Related]
13. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials.
Haverkamp H; Böll B; Eichenauer DA; Sasse S; Fuchs M; Borchmann P; Diehl V; Engert A; von Tresckow B
J Clin Oncol; 2015 Aug; 33(22):2430-6. PubMed ID: 26101245
[TBL] [Abstract][Full Text] [Related]
14. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis].
Tarasenkova AA; Filatova LV; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2012; 58(1):101-9. PubMed ID: 22629838
[TBL] [Abstract][Full Text] [Related]
15. A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly.
Wang E; Papavassiliou P; Sebastian S
Pathol Res Pract; 2012 Jun; 208(6):363-7. PubMed ID: 22572037
[TBL] [Abstract][Full Text] [Related]
16. Peroneal mononeuropathy in pediatric Hodgkin's disease.
Matsubara K; Nigami H; Harigaya H; Osaki M; Baba K
Leuk Lymphoma; 2000 Dec; 40(1-2):205-7. PubMed ID: 11426622
[TBL] [Abstract][Full Text] [Related]
17. [Treatment strategy of Hodgkin lymphoma].
Nagai H
Rinsho Ketsueki; 2014 Oct; 55(10):1941-51. PubMed ID: 25297759
[No Abstract] [Full Text] [Related]
18. Characteristics of children with non-hodgkin lymphoma associated with primary immune deficiency diseases: descriptions of five patients.
Emir S; Vezir E; Azkur D; Demir HA; Metin A
Pediatr Hematol Oncol; 2013 Sep; 30(6):544-53. PubMed ID: 23647505
[TBL] [Abstract][Full Text] [Related]
19. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
Borchmann P; Haverkamp H; Diehl V; Cerny T; Markova J; Ho AD; Eich HT; Mueller-Hermelink HK; Kanz L; Greil R; Rank A; Paulus U; Smardova L; Huber C; Dörken B; Nerl C; Krause SW; Mueller RP; Fuchs M; Engert A
J Clin Oncol; 2011 Nov; 29(32):4234-42. PubMed ID: 21990399
[TBL] [Abstract][Full Text] [Related]
20. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]